Mobile

A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Stati...

Mise à jour : Il y a 5 ans
Référence : EUCTR2007-002017-39

A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the LDL-C lowering efficacy of the addition of ER niacin/laropiprant to simvastatin or atorvastatin (pooled) compared with doubling the dose of simvastatin or atorvastatin (pooled) in patients with primary hypercholesterolemia or mixed dyslipidemia who are not at their NCEP ATP III LDL-C goal.

Critère d'inclusion

  • Hypercholesterolemia or Mixed Dyslipidemia

Liens